课题基金 / 基金详情

Completely biological tissue-engineered pulmonic valve grown in vitro from human

Completely biological tissue-engineered pulmonic valve grown in vitro from human
从人体体外培养的完全生物组织工程肺动脉瓣
批准号:
8083856
负责人:
ROBERT T TRANQUILLO
金额:
$56.87万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-04-01 至 2016-03-31

项目摘要

项目成果

ROBERT T TRANQUILLO的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The goal of this research plan is to translate the progress made with prior NIH funding into a completely biological tissue-engineered pulmonary valve replacement, made of tissue grown in vitro from fibroblast remodeled fibrin. This will be accomplished using (1) advances in heart valve bioreactor design and operation to strengthen the root segment and the root-leaflet attachment line, and (2) a new decellularization and optional recellularization strategy using mesenchymal stem cells to obviate the leaflet contraction that occurred post-implantation due to the transplanted fibroblasts, which are used to grow the tissue valve in vitro. This tissue-engineered heart valve (TEHV), both decellularized (relying on host cell invasion) and recellularized (with mesenchymal stem cells pre-implantation) will be validated in a lamb model to demonstrate growth capacity and sustained function of the engineered valve. Success will ultimately benefit approximately 10,000 pediatric patients in the U.S. annually and ultimately 100,000 patients in the U.S. annually if this TEHV can subsequently be improved to withstand forces associated with the aortic valve position. Enabling technologies relevant to other cardiovascular tissue engineering applications will be generated as a by-product of this research. PUBLIC HEALTH RELEVANCE: In the United States alone, over 95,000 valve replacement surgeries are now performed annually according to the AHA. While mechanical and bioprosthetic heart valves have made a dramatic impact since their introduction in the 1960's, the 10-year mortality after replacement is still 30-55%. The need is particularly great for pediatric patients, since these valves do not have the capacity to grow. Thus, there is great interest in developing a new generation of tissue-engineered heart valves and this research is aimed at the design and testing of a completely biological living valve replacement.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Biologically-engineered Transcatheter Vein Valve: Design Optimization and Preclinical Testing
  • 批准号:
    10594865
  • 项目类别:
  • 资助金额:
    $38.57万
  • 财政年份:
    2023
  • 负责人:
    ROBERT T TRANQUILLO
  • 依托单位:
Biopolymer-guided human stem cell assembly for engineered myocardium
  • 批准号:
    8328585
  • 项目类别:
  • 资助金额:
    $74.44万
  • 财政年份:
    2011
  • 负责人:
    ROBERT T TRANQUILLO
  • 依托单位:
Completely biological tissue-engineered pulmonic valve grown in vitro from human cells for pediatric patients
  • 批准号:
    10188591
  • 项目类别:
  • 资助金额:
    $72.11万
  • 财政年份:
    2011
  • 负责人:
    ROBERT T TRANQUILLO
  • 依托单位:
Perfusable and beating engineered myocardium from human progenitor cells based on
  • 批准号:
    8138261
  • 项目类别:
  • 资助金额:
    $71.56万
  • 财政年份:
    2011
  • 负责人:
    ROBERT T TRANQUILLO
  • 依托单位:
海外基金